Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
For more than a decade, BACE1 has been a prime target for designing drugs to prevent or treat AD.
|
22090477 |
2011 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
There were statistically significant correlations between plasma miRNA107 and BACE1 mRNA gene expression in Alzheimer's disease, amnestic mild cognitive impairment, and healthy control groups (r value = -0.316 [P = .002], -0.615 [P < .001], and -0.367 [P = .001], respectively).
|
25742200 |
2015 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Results reveal that SMC 1) reduces oxidative stress and neuro-inflammation; 2) modulates the distribution and levels of several metal ions; 3) decreases amyloid-β peptide (Aβ) generation by inhibiting the expression of its precursor protein APP and β-secretase (BACE1); and 4) attenuates tau hyperphosphorylation and neurofibrillary tangles (NFT) formation via promoting protein phosphatase 2A (PP2A) activity, thereby preserving synaptic proteins and neuron activities and finally improving spatial learning and memory deficits in AD model mice.
|
29688618 |
2018 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Herein, we highlight nine major targets associated with AD, which are acetylcholine esterase (AChE), beta-site amyloid precursor protein cleaving enzyme 1 (β-secretase, BACE-1), glycogen synthase kinase 3 beta (GSK-3β), monoamine oxidases (MAOs), metal ions in the brain, N-methyl-D-aspartate (NMDA) receptor, 5-hydroxytryptamine (5-HT) receptors, the third subtype of histamine receptor (H<sub>3</sub> receptor), and phosphodiesterases (PDEs), and their respective relationship to the disease network.
|
31103902 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD.
|
25481013 |
2014 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The inhibition of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), a key enzyme for Aβ production, is a promising target for AD therapy.
|
25779965 |
2015 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology.
|
22472085 |
2012 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MicroRNAs (miRNAs) are responsible for control of gene expression at the posttranscriptional level and are essential for the function of neuronal networks and neuronal survival. miRNA expression can impact the regulation of APP (amyloid beta A4 precursor protein), PSEN1 (presenilin 1), PSEN2 (presenilin 2), and BACE1 (beta-secretase 1) genes in the brain that were previously implicated in AD pathophysiology.
|
27501295 |
2016 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interestingly, addition of the dominant-negative mutant of Rab5, a small G-protein Rab5 involved in the endocytic process, inhibits the aging-related APP-BACE1 interaction and Abeta production, suggesting that endocytosis contributes to AD progression.
|
20127045 |
2010 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
|
30134967 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
BACE1 inhibitors hold potential as agents in disease-modifying treatment for Alzheimer's disease.
|
31021626 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.
|
29881722 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endoplasmic reticulum (ER) stress has emerged as one of the signaling pathways initiating and fostering the neurodegenerative changes in AD by increasing the aspartyl protease β-site AβPP cleaving enzyme 1 (BACE1) and amyloid-β (Aβ) genesis.
|
28304295 |
2017 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Meta-analyses on AD association with BACE1 exon 5, BACE1 intron 5, FE65 intron 13, CYP46 intron 2, alpha(1)-antichymotrypsine Ala17Thr, bleomycin hydrolase I443V, lectin-like oxidized low-density lipoprotein receptor (OLR1) 3'-UTR (+1071) and (+1073), and very-low-density lipoprotein receptor (VLDLR) 5'-UTR (CGG-repeat) polymorphisms.
|
17854420 |
2008 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
A copper-binding site in the cytoplasmic domain of BACE1 identifies a possible link to metal homoeostasis and oxidative stress in Alzheimer's disease.
|
17511654 |
2007 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
No difference in BACE1 levels was observed in AD MFC and in ND and AD MTC tissues.
|
23036023 |
2013 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Analysis of microRNAs (miRNAs) revealed that miR-9 and miR-181a negatively coregulated BACE1 and TGFBIp, which was directly associated with the pathogenesis of AD and GCD2, respectively.
|
30930125 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Hypomethylation of these enhancers in AD is associated with an upregulation of BACE1 transcripts and an increase in amyloid plaques, neurofibrillary tangles, and cognitive decline.
|
31113950 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Although increased BACE1 activity in Alzheimer disease brains and human (h) BACE1 transgenic (tg) mice results in altered APP cleavage, the contribution of these molecular alterations to neurodegeneration is unclear.
|
16027115 |
2005 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts.
|
19074428 |
2009 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results establish BACE1 and APP processing pathways as critical for cognitive, emotional, and synaptic functions, and future studies should be alert to potential mechanism-based side effects that may occur with BACE1 inhibitors designed to ameliorate Abeta amyloidosis in AD.
|
16354928 |
2005 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
β-Secretase (BACE1) has been broadly documented as one of the possible therapeutic targets for the treatment of Alzheimer's disease.
|
30502632 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results indicate that Bace1 inhibitors, currently in clinical trials for Alzheimer's disease, may be useful agents for the treatment of obesity and associated diabetes.
|
29311632 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
It has been suggested that cholesterol may modulate amyloid-beta (Abeta) formation, a causative factor of Alzheimer's disease (AD), by regulating distribution of the three key proteins in the pathogenesis of AD (beta-amyloid precursor protein (APP), beta-secretase (BACE1) and/or presenilin 1 (PS1)) within lipid rafts.
|
20138836 |
2010 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results suggest that lentiviral vector delivery of BACE1 siRNA can specifically reduce the cleavage of APP and neurodegeneration in vivo and indicate that this approach could have potential therapeutic value for treatment of Alzheimer disease.
|
16136043 |
2005 |